Outlook Therapeutics Provides a Corporate Update and Business Outlook
January 25, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarterONS-5010 / LYTENAVA™...
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
January 19, 2022 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 08:35 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update
December 22, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal...
Outlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia
December 15, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) Congress
December 09, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
November 29, 2021 16:15 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the...
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
November 23, 2021 22:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the...
Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
November 23, 2021 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first...
Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
November 13, 2021 11:00 ET
|
Outlook Therapeutics, Inc.
- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ...